EP 3452514 A1 20190313 - T-CELL IMMUNOTHERAPY SPECIFIC FOR MART-1
Title (en)
T-CELL IMMUNOTHERAPY SPECIFIC FOR MART-1
Title (de)
MART-1-SPEZIFISCHE T-ZELL-IMMUNTHERAPIE
Title (fr)
IMMUNOTHÉRAPIE DE LYMPHOCYTES T SPÉCIFIQUE DE MART-1
Publication
Application
Priority
- US 201662333117 P 20160506
- US 2017031453 W 20170505
Abstract (en)
[origin: WO2017193104A1] The present disclosure provides T cell receptors specific for human melanoma antigen recognized by T cells 1 (MART-1) epitopes for use in treating diseases or disorders, such as cancer cells that overexpress MART-1.
IPC 8 full level
C07K 16/30 (2006.01); A61K 39/395 (2006.01)
CPC (source: EP)
A61K 39/39541 (2013.01); A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/46444 (2023.05); A61K 39/464456 (2023.05); A61K 39/464491 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2818 (2013.01); C07K 16/3053 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
DOCDB simple family (application)
US 2017031453 W 20170505; EP 17724686 A 20170505